Outlook Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Outlook Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- OTLK
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001649989
Board of directors
-
Andong Huang · DirectorSince 2023
-
C. Russell Trenary III · Director · CEO AND PRESIDENTSince 2023
-
Faisal Ghiath Sukhtian · DirectorSince 2023
-
Gerd Auffarth · DirectorSince 2023
-
Ghiath M. Sukhtian · DirectorSince 2024
-
Julia A. Haller · DirectorSince 2023
-
Julian S. Gangolli · DirectorSince 2023
-
Kurt J. Hilzinger · DirectorSince 2023
-
Lawrence A. Kenyon · Director · Chief Financial OfficerSince 2024
-
Randy H. Thurman · DirectorSince 2023
-
Robert Charles Jahr · Director · Chief Executive OfficerSince 2026
-
Yezan Munther Haddadin · DirectorSince 2023
Chief executives
C. Russell Trenary III
· CEO and President
Dates unknown
Robert Charles Jahr
· Chief Executive Officer
Dates unknown
Board connections
3 of this board's directors also sit on 3 other boards.
- via Julia A. Haller
- via Kurt J. Hilzinger
- via Julian S. Gangolli
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $7,905,695
- 10 purchases by 8 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 14, 2026 | Robert Charles Jahr Director, Officer (Chief Executive Officer) | Open-market purchase | +151,515 | — | — |
| Aug 14, 2026 | Lawrence A. Kenyon Director, Officer (Chief Financial Officer) | Open-market purchase | +101,010 | — | — |
| Aug 12, 2026 | Ghiath M. Sukhtian Director, 10% owner | Open-market purchase | +2,525,252 | $0.99 | $2,499,999 |
| Jul 29, 2026 | Faisal Ghiath Sukhtian Director | Open-market purchase | +95,398 | $1.05 | $99,996 |
| Jun 2, 2026 | Yezan Munther Haddadin Director | Open-market purchase | +29,000 | $0.83 | $24,070 |
| May 28, 2026 | GMS Ventures & Investments Director, 10% owner | Open-market purchase | +8,539,709 | $0.59 | $5,038,428 |
| May 27, 2026 | Faisal Ghiath Sukhtian Director | Open-market purchase | +122,174 | $0.41 | $50,091 |
| May 26, 2026 | Yezan Munther Haddadin Director | Open-market purchase | +34,000 | $0.44 | $14,960 |
| May 26, 2026 | Randy H. Thurman Director | Open-market purchase | +5,000 | $0.43 | $2,150 |
| May 26, 2026 | Kurt J. Hilzinger Director | Open-market purchase | +400,000 | $0.44 | $176,000 |
| May 27, 2025 | Ghiath M. Sukhtian Director, 10% owner | Grant or award | +4,285,714 | $1.40 | $6,000,000 |
| Sep 26, 2024 | Lawrence A. Kenyon Director, Officer (Chief Financial Officer) | Open-market purchase | +5,000 | $5.69 | $28,450 |
| Apr 15, 2024 | Syntone Ventures LLC 10% owner | Open-market purchase | +714,286 | — | — |
| Mar 28, 2024 | Yezan Munther Haddadin Director | Open-market purchase | +1,882 | $11.82 | $22,242 |
| Mar 18, 2024 | Ghiath M. Sukhtian Director, 10% owner | Grant or award | +2,305,714 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.